Documents & Downloads

Itanistomig

Itanistomig is a bispecific antibody designed to target CD274 and CD47. Structurally characterized as VH-G1CH1-h-H-γ1_L-κ-L-κ, this antibody facilitates dual engagement with these critical immune checkpoint proteins, enhancing the potential for immune system modulation in therapeutic applications. Itanistomig is engineered for high specificity and affinity, making it a valuable tool in research focused on cancer immunotherapy and immune regulation.

In Stock

Biological Activity

Target & Activity

CD274/CD47

Product Details

Manufacturer Adooq Bioscience
CAS Number 2923687-56-1

Storage

Store lyophilized at -20°C, keep desiccated.
In lyophilized form, the antibody is stable for 36 months.
After reconstitution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Customer Questions
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research. Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
Loading...

Added to your cart

View Cart Checkout
Loading...